Novo Nordisk, Hims & Hers Health
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $20.36 which represents a slight increase of $1.53 or 8.13% from the prior close of $18.83. The stock opened at ...
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
Seaport Global analyst Aaron Kessler maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price ...
Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback